DeWittEMKimuraYBeukelmanT, et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2012;64(7):1001-1010. doi:10.1002/acr.21625.
2.
LeeJJYSchneiderR. Systemic juvenile idiopathic arthritis. Pediatr Clin North Am. 2018;65(4):691-709.
3.
BehrensEMBeukelmanTGalloL, et al. Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). J Rheumatol. 2008;35(2):343-348.
4.
VastertSJKuisWGromAA. Systemic JIA: new developments in the understanding of the pathophysiology and therapy. Best Pract Res Clin Rheumatol. 2009;23(5):655-664. doi:10.1016/j.berh.2009.08.003.
5.
PettyRESouthwoodTRMannersP, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390-392.
6.
LynchJPatraKPVijayCMitchellMMoffett-BradfordK. A case of fever of unknown origin. Hosp Pediatr. 2015;5(8):452-455. doi:10.1542/hpeds.2014-0238.
7.
GoldmuntzEAWhitePH. Juvenile idiopathic arthritis: a review for the pediatrician. Pediatr Rev. 2006;27(4):e24-e32. doi:10.1542/pir.27-4-e24.
8.
SreenivasanPManiNS. Pure red cell aplasia in systemic onset juvenile idiopathic arthritis. Indian J Hematol Blood Transfus. 2011;28(1):42-43. doi:10.1007/s12288-011-0085-z.
SaperVEChenGDeutschGH, et al. Emergent high fatality lung disease in systemic juvenile arthritis. Ann Rheum Dis. 2019;78(12):1722-1731. doi:10.1136/annrheumdis-2019-216040.
11.
SchulertGSYasinSCareyB, et al. Systemic juvenile idiopathic arthritis–associated lung disease: characterization and risk factors. Arthritis Rheumatol. 2019;71(11):1943-1954. doi:10.1002/art.41073.
12.
KimuraYWeissJEHaroldsonKL, et al. Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2013;65(5):745-752. doi:10.1002/acr.21889.
13.
CannySMellinsE. New frontiers in the treatment of systemic juvenile idiopathic arthritis. F1000Res. 2017;6:971. doi:10.12688/f1000research.11327.1.
14.
JungJYKimMYSuhCHKimH-A. Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review. Pediatric Rheumatology Online J. 2018;16(1):79. doi:10.1186/s12969-018-0296-z.
15.
SukharomanaMUdomittipongKRuangchira-uraiRCharuvanijS. Nonspecific interstitial pneumonia in refractory systemic juvenile idiopathic arthritis responded to tocilizumab treatment. Asian Pac J Allergy Immunol. 2022;40:172-176. doi:10.12932/ap-050819-0616.
